Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: J Allergy Clin Immunol. 2018 Mar 2;142(5):1479–1488.e12. doi: 10.1016/j.jaci.2017.11.059

Figure 1.

Figure 1

Study Design Diagram. We used 104 participants of the CAMP clinical trial all randomized to the budesonide ICS treatment arm. Each was assessed along 6 longitudinal measures of steroid treatment for the duration of the original CAMP trial (4 years) to obtain their Steroid Responsiveness Endophenotype (SRE) value, measuring the effectiveness of ICS therapy at managing asthma. These subjects further provided blood samples which were immortalized and treated with both a steroid, Dexamethasone, and a sham treatment. LCL DEX response and genome-wide SNPs from these participants were used in the REFS network modeling framework to identify a number of genes that interacted with SRE. Three of these seven genes were validated in lung epithelial cell lines, and FAM129A was shown to be significantly associated with IL1B under steroid treatment.